Objective: To investigate the relationship between newly identified senataxin (SETX) gene mutations and the clinical manifestation of Amyotrophic Lateral Sclerosis (ALS), enhancing understanding of the genetic underpinnings associated with this disorder.
Methods: A cohort study was conducted at Nanfang Hospital, involving comprehensive genetic sequencing of ALS patients to identify novel SETX mutations. Homology modelling and structural analysis were employed to predict the functional impacts of these mutations on the senataxin protein. Clinical assessments, including symptom evaluation, age of onset, and progression rate, were integrated with electrophysiological studies to establish correlations between genetic variants and clinical outcomes.
Results: Ten novel SETX mutations were identified, expanding the genetic landscape of ALS. These mutations exhibited diverse impacts on clinical presentations, with patients showing variability in onset age, symptom severity, and progression rates. Computational modelling suggested that certain mutations cause significant structural changes in senataxin, potentially affecting its RNA/DNA helicase function. Electrophysiological findings consistently revealed nerve conduction abnormalities, indicating that these mutations may influence neuronal excitability and contribute to ALS pathogenesis.
Conclusion: The discovery of novel SETX mutations provides valuable insights into the genetic and clinical complexity of ALS. This study underscores the importance of genetic screening for SETX mutations and suggests potential personalised therapeutic approaches targeting senataxin dysfunction. By elucidating genotype-phenotype correlations, these findings contribute to the broader understanding of ALS and offer pathways for developing targeted interventions to address the challenges posed by this disabling disease.
Keywords: SETX mutations; amyotrophic lateral sclerosis.